The role of biologic agents in the management of non-infectious uveitis

Jangwon Heo, Yasir J. Sepah, Jithin Yohannan, Morgan Renner, Abeer Akhtar, Anthony Gregory, Mathew Shulman, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Introduction: Uveitis is an intriguing group of disorders characterized by inflammation of the uveal tract. Due to the potential grave consequences of the disease process, it is important to assess the various therapeutic options available for treating uveitis, and their outcomes. Areas covered: This review discusses the use of conventional agents in the management of uveitis, including discussion of the molecular and clinical properties of corticosteroids, antimetabolites, calcineurin inhibitors and alkylating agents and their side effects. In addition, it also discusses the molecular and clinical properties of novel biologic agents and their side effects. Moreover, recommendations as to when biologic agents should be employed are also discussed. Expert opinion: We recommend that in general (except in selected cases of Adamantiades- Behçet's disease) biologics should not be used as a first-line therapy for uveitis due to inconvenience, high cost, and potential immunosuppressive effects. However, many biologics are potent in inducing drug-free remission of uveitis and may be employed to manage recurrent diseases or diseases not responsive to conventional agents.

Original languageEnglish (US)
Pages (from-to)995-1008
Number of pages14
JournalExpert Opinion on Biological Therapy
Volume12
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Uveitis
Biological Factors
Biological Products
Antimetabolites
Alkylating Agents
Immunosuppressive Agents
Graves Disease
Expert Testimony
Adrenal Cortex Hormones
Inflammation
Costs and Cost Analysis
Pharmaceutical Preparations
Costs
Therapeutics

Keywords

  • biologics
  • intermediate
  • panuveitis
  • posterior

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Heo, J., Sepah, Y. J., Yohannan, J., Renner, M., Akhtar, A., Gregory, A., ... Nguyen, Q. D. (2012). The role of biologic agents in the management of non-infectious uveitis. Expert Opinion on Biological Therapy, 12(8), 995-1008. https://doi.org/10.1517/14712598.2012.688021

The role of biologic agents in the management of non-infectious uveitis. / Heo, Jangwon; Sepah, Yasir J.; Yohannan, Jithin; Renner, Morgan; Akhtar, Abeer; Gregory, Anthony; Shulman, Mathew; Do, Diana V.; Nguyen, Quan Dong.

In: Expert Opinion on Biological Therapy, Vol. 12, No. 8, 01.08.2012, p. 995-1008.

Research output: Contribution to journalReview article

Heo, J, Sepah, YJ, Yohannan, J, Renner, M, Akhtar, A, Gregory, A, Shulman, M, Do, DV & Nguyen, QD 2012, 'The role of biologic agents in the management of non-infectious uveitis', Expert Opinion on Biological Therapy, vol. 12, no. 8, pp. 995-1008. https://doi.org/10.1517/14712598.2012.688021
Heo, Jangwon ; Sepah, Yasir J. ; Yohannan, Jithin ; Renner, Morgan ; Akhtar, Abeer ; Gregory, Anthony ; Shulman, Mathew ; Do, Diana V. ; Nguyen, Quan Dong. / The role of biologic agents in the management of non-infectious uveitis. In: Expert Opinion on Biological Therapy. 2012 ; Vol. 12, No. 8. pp. 995-1008.
@article{6b7e482ff5ec4963bfc0f465f2415da8,
title = "The role of biologic agents in the management of non-infectious uveitis",
abstract = "Introduction: Uveitis is an intriguing group of disorders characterized by inflammation of the uveal tract. Due to the potential grave consequences of the disease process, it is important to assess the various therapeutic options available for treating uveitis, and their outcomes. Areas covered: This review discusses the use of conventional agents in the management of uveitis, including discussion of the molecular and clinical properties of corticosteroids, antimetabolites, calcineurin inhibitors and alkylating agents and their side effects. In addition, it also discusses the molecular and clinical properties of novel biologic agents and their side effects. Moreover, recommendations as to when biologic agents should be employed are also discussed. Expert opinion: We recommend that in general (except in selected cases of Adamantiades- Beh{\cc}et's disease) biologics should not be used as a first-line therapy for uveitis due to inconvenience, high cost, and potential immunosuppressive effects. However, many biologics are potent in inducing drug-free remission of uveitis and may be employed to manage recurrent diseases or diseases not responsive to conventional agents.",
keywords = "biologics, intermediate, panuveitis, posterior",
author = "Jangwon Heo and Sepah, {Yasir J.} and Jithin Yohannan and Morgan Renner and Abeer Akhtar and Anthony Gregory and Mathew Shulman and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2012",
month = "8",
day = "1",
doi = "10.1517/14712598.2012.688021",
language = "English (US)",
volume = "12",
pages = "995--1008",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - The role of biologic agents in the management of non-infectious uveitis

AU - Heo, Jangwon

AU - Sepah, Yasir J.

AU - Yohannan, Jithin

AU - Renner, Morgan

AU - Akhtar, Abeer

AU - Gregory, Anthony

AU - Shulman, Mathew

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Introduction: Uveitis is an intriguing group of disorders characterized by inflammation of the uveal tract. Due to the potential grave consequences of the disease process, it is important to assess the various therapeutic options available for treating uveitis, and their outcomes. Areas covered: This review discusses the use of conventional agents in the management of uveitis, including discussion of the molecular and clinical properties of corticosteroids, antimetabolites, calcineurin inhibitors and alkylating agents and their side effects. In addition, it also discusses the molecular and clinical properties of novel biologic agents and their side effects. Moreover, recommendations as to when biologic agents should be employed are also discussed. Expert opinion: We recommend that in general (except in selected cases of Adamantiades- Behçet's disease) biologics should not be used as a first-line therapy for uveitis due to inconvenience, high cost, and potential immunosuppressive effects. However, many biologics are potent in inducing drug-free remission of uveitis and may be employed to manage recurrent diseases or diseases not responsive to conventional agents.

AB - Introduction: Uveitis is an intriguing group of disorders characterized by inflammation of the uveal tract. Due to the potential grave consequences of the disease process, it is important to assess the various therapeutic options available for treating uveitis, and their outcomes. Areas covered: This review discusses the use of conventional agents in the management of uveitis, including discussion of the molecular and clinical properties of corticosteroids, antimetabolites, calcineurin inhibitors and alkylating agents and their side effects. In addition, it also discusses the molecular and clinical properties of novel biologic agents and their side effects. Moreover, recommendations as to when biologic agents should be employed are also discussed. Expert opinion: We recommend that in general (except in selected cases of Adamantiades- Behçet's disease) biologics should not be used as a first-line therapy for uveitis due to inconvenience, high cost, and potential immunosuppressive effects. However, many biologics are potent in inducing drug-free remission of uveitis and may be employed to manage recurrent diseases or diseases not responsive to conventional agents.

KW - biologics

KW - intermediate

KW - panuveitis

KW - posterior

UR - http://www.scopus.com/inward/record.url?scp=84863803023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863803023&partnerID=8YFLogxK

U2 - 10.1517/14712598.2012.688021

DO - 10.1517/14712598.2012.688021

M3 - Review article

C2 - 22780091

AN - SCOPUS:84863803023

VL - 12

SP - 995

EP - 1008

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 8

ER -